Antipsychotic properties of muscarinic drugs.
Janowsky
David S
DS
Davis
John M
JM
D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D018678:Cholinergic Agents / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007531:Isoflurophate / Q000009:adverse effects / Q000627:therapeutic use; D010830:Physostigmine / Q000009:adverse effects / Q000627:therapeutic use; D011605:Psychoses, Substance-Induced / Q000209:etiology; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D051381:Rats; D012559:Schizophrenia / Q000188:drug therapy*; D013830:Thiadiazoles / Q000009:adverse effects / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D018678:Cholinergic Agents; D002800:Cholinesterase Inhibitors; D011725:Pyridines; D013830:Thiadiazoles; D007531:Isoflurophate; C075257:xanomeline; D010830:Physostigmine